ATE505538T1 - Dna-vektoren - Google Patents

Dna-vektoren

Info

Publication number
ATE505538T1
ATE505538T1 AT04754961T AT04754961T ATE505538T1 AT E505538 T1 ATE505538 T1 AT E505538T1 AT 04754961 T AT04754961 T AT 04754961T AT 04754961 T AT04754961 T AT 04754961T AT E505538 T1 ATE505538 T1 AT E505538T1
Authority
AT
Austria
Prior art keywords
dna vectors
cancer
treatment
methods
present
Prior art date
Application number
AT04754961T
Other languages
English (en)
Inventor
Gregory Spies
Lynda Misher
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE505538T1 publication Critical patent/ATE505538T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AT04754961T 2003-06-09 2004-06-09 Dna-vektoren ATE505538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47723203P 2003-06-09 2003-06-09
PCT/US2004/018529 WO2005002509A2 (en) 2003-06-09 2004-06-09 Dna vectors

Publications (1)

Publication Number Publication Date
ATE505538T1 true ATE505538T1 (de) 2011-04-15

Family

ID=33563762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04754961T ATE505538T1 (de) 2003-06-09 2004-06-09 Dna-vektoren

Country Status (8)

Country Link
US (1) US20100150968A1 (de)
EP (1) EP1639109B1 (de)
JP (1) JP4771954B2 (de)
AT (1) ATE505538T1 (de)
CA (1) CA2528094A1 (de)
DE (1) DE602004032235D1 (de)
ES (1) ES2363972T3 (de)
WO (1) WO2005002509A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2325306T3 (pl) 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
AU2008247881A1 (en) 2007-04-30 2008-11-13 Interdigital Technology Corporation Cell reselection and handover with multimedia broadcast/multicast service
US20120129770A1 (en) * 2009-06-22 2012-05-24 Rajyashri Karur Ramakrishna Novel polynucleotide molecules for enhanced gene expression
AU2012243463B2 (en) * 2011-04-15 2017-04-13 Cecilia Naucler Genetic variant of cytomegalovirus (CMV)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6518256B1 (en) * 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
WO2002031137A2 (en) * 2000-10-13 2002-04-18 Chiron Corporation Cytomegalovirus intron a fragments

Also Published As

Publication number Publication date
US20100150968A1 (en) 2010-06-17
ES2363972T3 (es) 2011-08-22
CA2528094A1 (en) 2005-01-13
WO2005002509A3 (en) 2005-06-02
JP4771954B2 (ja) 2011-09-14
EP1639109B1 (de) 2011-04-13
JP2007506443A (ja) 2007-03-22
EP1639109A2 (de) 2006-03-29
EP1639109A4 (de) 2007-07-04
WO2005002509A2 (en) 2005-01-13
DE602004032235D1 (de) 2011-05-26

Similar Documents

Publication Publication Date Title
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
EP1844077A4 (de) Dr5-antikörper und deren verwendung
TW200732349A (en) Anti-OX40L antibodies and methods using same
TW200611910A (en) Interferon-alpha polypeptides and conjugates
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
EA200800094A1 (ru) Антитела cd19 и их использование
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
SE0301650D0 (sv) Novel compounds
ATE486931T1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
EP1738654A4 (de) Sojaproteinhaltige(s) lösung und gel
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
DE602004032235D1 (de) Dna-vektoren
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
ATE425962T1 (de) Peptid-deformylase-hemmer
ATE328000T1 (de) Phospholipidester von clofarabin
ATE420162T1 (de) Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties